

CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

To,

Date: 14.12.2017

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai -400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.12.2017

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of M/s. Concord Drugs Limited held on Thursday, 14.12.2017 at 4:30 p.m. at the registered office of the company at Survey No. 249, Brahmanapally Village, Hayatnagar Mandal - 501511, Telangana the following were considered and approved:

1. Un-audited financial results for the quarter ended 30.09.2017. (Attached)
2. Limited Review Report for the quarter ended 30.09.2017. (Attached)

The meeting concluded at 5.00 p.m.


This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Chairman and whole-time Director
DIN: 01764665



Encl: as above



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

CONCORD DRUGS LIMITED							
Statement of Un-Audited Results for the Quarter ended 30.09.2017							
S.No.	Particulars	Quarter Ended			Half year Ended		Year Ended
		30.09.2017 Un-Audited	30.06.2017 Un-Audited	30.09.2016 Un-Audited	30.09.2017 Un-Audited	30.09.2016 Un-Audited	31.03.2017 Audited
I	Revenue from Operations						
II	Other Income	376.71	2,097.34	1,388.96	2,474.05	2,684.44	5,748.97
III	Total income (I+II)	-	0.98	1.59	0.98	3.54	8.57
IV	Expenses	376.71	2,098.32	1,390.55	2,475.03	2,687.98	5,757.54
	(a) Cost of Materials consumed			1,073.64		2,209.26	4,650.89
	(b) Purchase of stock-in-trade	163.25	2,204.31	-	2,367.56	-	-
	(c) Changes in inventories of finished goods, work-in-progress and	(41.37)	(347.27)	25.25	(388.64)	(68.64)	(40.38)
	(d) Employee benefits expense	83.79	55.60	59.65	139.39	111.33	280.65
	(e) Finance Cost	30.03	57.80	55.05	87.83	112.00	235.99
	(f) Depreciation and amortisation expense	57.32	54.97	63.62	112.29	122.46	258.40
	(h) Other expenses	75.26	66.86	63.80	142.12	114.12	307.24
	Total Expenses	368.28	2,092.27	1,341.01	2,460.55	2,600.53	5,692.79
V	Profit / (Loss) before and exceptional items and Tax (III-IV)	8.43	6.05	49.54	14.48	87.45	64.75
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) from before tax (V-VI)	8.43	6.05	49.54	14.48	87.45	64.75
VIII	Tax expense						
	Current Tax	2.53	1.81	14.86	4.34	26.23	35.72
	Deferred Tax	-	-	-	-	-	9.42
IX	Net Profit / (Loss) after Tax (VII-VIII)	5.90	4.24	34.68	10.14	61.22	19.61
X	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XI	Total Comprehensive Income	5.90	4.24	34.68	10.14	61.22	19.61
XII	Paid-up equity share capital (Face Value of Rs. 10/- per share)	724.80	724.80	724.80	724.80	724.38	724.80
XIII	Earnings Per Equity Share of face value of Rs.10/- each						
	a) Basic & Diluted (In Rs.)	0.08	0.06	0.48	0.14	0.85	0.27

Date: 14.12.2017
Place: Hyderabad

For CONCORD DRUGS LIMITED

S. N. Reddy
Nagi Reddy Seelam
Chairman & Wholetime Director
DIN: 01764665





CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

NOTES

- 1 The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 13.12.2017
- 2 The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. The Ind-AS Compliant Standardlone Financial results for the corresponding quarter ended June 30, 2016 have been stated in terms of SEBI Circular dated July, 05, 2016.
- 3 Reconciliation of results between previously reported (referred to as "Previous GAAP") and Ind-AS for the corresponding quarter and Half Year ended September 30, 2016 is as under;

Particulars	Quarter ended 30th Sep, 2016	Half Year 30th Sep, 2016
Net Profit/(Loss) after Tax under Indian GAAP	34.68	61.22
Details of Ind-As Adjustments		
Impairment of Fixed Assets	-	-
Other	-	-
Net Profit for the period as per Ind-AS	34.68	61.22
Add: Other Comprehensive Income	-	-
Total Comprehensive Income for the Period as per Ind-AS	34.68	61.22

- 4 The results are also available on the website of the Company www.abhishekinfra.co.in.
- 5 The Company is engaged in "Manufacturing of Pharmaceuticals" operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments"

Station: Hyderabad
Date : 14.12.2017

For CONCORD DRUGS LIMITED

S. N. Reddy
Nagi Reddy Soelam
Chairman & Wholetime Director
DIN:01764665





CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
 Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsLtd@gmail.com, web : www.concorddrugs.in

CONCORD DRUGS LIMITED
 Balance Sheet as at 30th September 2017

		Amount in Lakhs	
Particulars		As at 30-09-2017	As at 31-03-2017
I	ASSETS:		
1	NON-CURRENT ASSETS:		
	(a) Property, Plant and Equipment	1,278.45	1,363.52
	(b) Capital work-in-progress	-	-
	(c) Investment Property	-	-
	(d) Goodwill	-	-
	(e) Other Intangible Assets	-	-
	(f) Intangible Assets under development	-	-
	(g) Biological Assets other than bearer plants	-	-
	(h) Financial Assets	-	-
	(i) Investments	-	-
	(ii) Loans	114.55	114.55
	(iii) Others	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	-
		1,393.00	1,478.07
2	CURRENT ASSETS:		
	(a) Inventories	1,491.34	1,102.70
	(b) Financial Assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	5,743.12	4,573.15
	(iii) Cash and cash equivalents	8.15	17.14
	(iv) Bank balances other than (iii) above	-	-
	(v) Loans	115.91	90.71
	(vi) Others (to be specified)	-	-
	(c) Current Tax Assets (Net)	-	-
	(d) Other current assets	243.81	240.83
		7,602.33	6,024.53
	TOTAL	8,995.33	7,502.60
II	EQUITY AND LIABILITIES:		
1	EQUITY:		
	(a) Equity Share Capital	724.38	724.38
	(b) Other Equity	811.92	801.78
		1,536.30	1,526.16
2	LIABILITIES:		
i	NON-CURRENT LIABILITIES:		
	(a) Financial Liabilities		
	(i) Borrowings	931.80	1,062.82
	(ii) Trade Payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	9.29	9.29
	(c) Deferred tax liabilities (Net)	27.36	27.36
	(d) Other non-current liabilities	-	-
		968.45	1,099.47
ii	CURRENT LIABILITIES:		
	(a) Financial Liabilities		
	(i) Borrowings	979.42	926.08
	(ii) Trade payables	5,111.54	3,586.47
	(iii) Other financial liabilities (other than those specified in item (c))	-	-
	(b) Other current liabilities	395.28	328.70
	(c) Provisions	4.34	35.72
	(d) Current Tax Liabilities (Net)	-	-
		6,490.58	4,876.97
	TOTAL	8,995.33	7,502.60

Date: 13.12.2017
 Place: Hyderabad

For CONCORD DRUGS LIMITED

S. N. Reddy
 Nagi Reddy Seelam
 Chairman & Wholetime Director
 DIN:01764665





LIMITED REVIEW REPORT

To,
The Board of Directors,
CONCORD DRUGS LIMITED

We have reviewed the accompanying statement of Un-audited Financial Results of **CONCORD DRUGS LIMITED** for the quarter ended and half year ended 30th September, 2017 attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14th December, 2017

For, **M M REDDY & CO.,**
Chartered Accountants
Chartered Accountants

M. Madhusudhana Reddy
Partner
Membership No. 213077